Pipeline — registered trials by phase
Evaluation of the QuantiFERON-TB Test.
— · Tuberculosis · Completed · est. 2015-10
QIAstat-Dx® Respiratory Panel Plus (RPP) Clinical Performance Study
— · Respiratory Disease · Completed · est. 2023-05-03
Evaluation of the QuantiFERON-TB Test.
— · Tuberculosis · Completed · est. 2016-03-28
Clinical Performance of QIAstat-Dx® Gastrointestinal Panel 2
— · Gastrointestinal Infection · Completed · est. 2021-12-31
Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit
— · Non-Small Cell Lung Cancer, Colorectal Cancer · Completed · est. 2020-11-23
QIAstat-Dx® BCID Plus AMR Panels Clinical Performance Study
— · Blood Disease · Completed · est. 2025-04-10
Testing of DNA Extracted From Tumor Tissue Biopsy Samples Using Therascreen KRAS RGQ PCR Kit
— · Non Small Cell Lung Cancer · Completed · est. 2022-05-26
Clinical Performance Evaluation of the NeuMoDx™ EBV Quant Assay 2.0 in Immunocompromised Transplant Patients
— · EBV Viremia · Completed · est. 2023-12-31
Clinical Performance of QIAstat-Dx® Meningitis/Encephalitis (ME) Panel Plus
— · Meningitis, Encephalitis Infection · Active Not Recruiting · est. 2026-05-15
Clinical Study Testing DNA Extracted From Tumour Tissue Biopsy Samples, Using the Therascreen® KRAS RGQ PCR Kit
— · Non-small Cell Lung Cancer · Completed · est. 2021-04-22
Clinical Performance Evaluation of the NeuMoDx™ FluA/FluB/RSV/Severe Acute Respiratory Syndrome-CoV-2 Assay
— · Respiratory Disease · Completed · est. 2024-02-07
Evaluation of the Artus® CMV PCR Test
— · Cytomegalovirus Infections · Completed · est. 2013-09
Collection and Extraction of Respiratory Specimens
— · Influenza · Completed · est. 2010-05
Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR
— · Complicated Urinary Tract Infection · Active Not Recruiting · est. 2026-08
QIAstat-Dx® Meningitis/Encephalitis Panel Performance Evaluation Study
— · Meningitis/Encephalitis · Completed · est. 2023-03-02
DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit
— · Metastatic Colorectal Cancer (mCRC) · Recruiting · est. 2030-10-31
QIAstat-Dx® Meningitis/Encephalitis Panel Performance Evaluation Study 001
— · Meningitis/Encephalitis · Completed · est. 2021-12-02
Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection
— · Tuberculosis · Completed · est. 2015-11-07
Evaluation of the QuantiFERON-TB Test.
— · Tuberculosis · Completed · est. 2016-04-26
Collection and Testing of Respiratory Samples
— · QIAGEN ResPlex II Advanced Panel, Influenza A, Respiratory Syncytial Virus Infections · Completed · est. 2011-07
Therascreen® KRAS RGQ PCR Kit
— · Colo-rectal Cancer · Completed · est. 2023-03-30
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Qiagen is lead sponsor; 21 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 6-K2026-09-09Report of foreign issuer
- 6-K2026-08-07Report of foreign issuer
- 6-K2026-08-07Report of foreign issuer
- 6-K2026-08-07Report of foreign issuer
- SCHEDULE 13G/A2026-06-05SCHEDULE 13G/A
- SD2026-06-01SD
- 6-K2026-05-08Report of foreign issuer
- 6-K2026-05-08Report of foreign issuer
- 6-K2026-05-01Report of foreign issuer
- IRANNOTICE2026-03-20IRANNOTICE
- 20-F2026-03-20Annual report (foreign)
- SCHEDULE 13G/A2026-02-10SCHEDULE 13G/A
- SCHEDULE 13G2026-02-06SCHEDULE 13G
- 6-K2026-02-06Report of foreign issuer
- 25-NSE/A2026-01-0925-NSE/A
- 25-NSE2026-01-0825-NSE
- 6-K2025-12-22Report of foreign issuer
- SCHEDULE 13G/A2025-11-12SCHEDULE 13G/A
- 6-K2025-11-06Report of foreign issuer
- 6-K2025-11-06Report of foreign issuer
- 6-K2025-09-02Report of foreign issuer
- 6-K2025-08-21Report of foreign issuer
- SCHEDULE 13G/A2025-08-12SCHEDULE 13G/A
- 6-K2025-08-07Report of foreign issuer
- 6-K2025-06-30Report of foreign issuer
- SD2025-06-02SD
- SCHEDULE 13G/A2025-05-14SCHEDULE 13G/A
- 6-K2025-05-13Report of foreign issuer
- 6-K2025-05-09Report of foreign issuer
- 6-K2025-04-09Report of foreign issuer
- IRANNOTICE2025-03-31IRANNOTICE
- 20-F2025-03-31Annual report (foreign)
- 6-K2025-02-07Report of foreign issuer
- SCHEDULE 13G2025-02-06SCHEDULE 13G
- 6-K2025-01-16Report of foreign issuer
- 6-K2025-01-13Report of foreign issuer
- SC 13G2024-11-08Passive large holder (>5%)
- 6-K2024-11-08Report of foreign issuer
- 6-K2024-11-08Report of foreign issuer
- 6-K2024-11-08Report of foreign issuer
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.